Medical Policy Updates

Notification of Policy Revisions Effective April 1, 2021 Posted January 12, 2021

Medical Policy Revision
Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid Leukemia In the Non-Hematopoietic Stem Cell Transplant Setting Under "When Covered" for Rituxan (rituximab), added Riabni (rituximab-arrx) biosimilar with same indications and coverage criteria as Rituxan (rituximab). Reference added. Medical Director review 1/2021. Policy notification given 1/12/2021 for effective date 4/1/2021.